Back to search

Netherlands· NL-bd834b3de7ee

Abrysvo poeder en oplosmiddel voor oplossing voor injectie

A respiratorisches-synzytial-virus impfstoffe product containing recombinant respiratoir syncytieel virus subgroep a prefusie f antigeen 847a + recombinant respiratoir syncytieel virus subgroep b prefusie f antigeen 847b, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 11 of our 19 countries.

ATC J07BX05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAbrysvo poeder en oplosmiddel voor op…ATCJ07BX05REGISTER NO.NL-bd834b3de7eePACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Respiratorisches-synzytial-virus impfstoffe is registered in 11 of 19 countries.

Countries holding a registration under ATC J07BX05 (respiratorisches-synzytial-virus impfstoffe), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Respiratorisches-synzytial-virus impfstoffe · ATC J07BX05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RECOMBINANT RESPIRATOIR SYNCYTIEEL VIRUS SUBGROEP A PREFUSIE F ANTIGEEN 847A + RECOMBINANT RESPIRATOIR SYNCYTIEEL VIRUS SUBGROEP B PREFUSIE F ANTIGEEN 847B
Manufacturer
Pfizer Europe MA EEIG
Country
Netherlands (NL)
ATC code
J07BX05
ATC class
Respiratorisches-Synzytial-Virus Impfstoffe
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1752

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8beb20cd-df04-4f77-8228-c94d0e870294
GET /v1/drugs/8beb20cd-df04-4f77-8228-c94d0e870294?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor oplossing voor injectie",
  "route": "Intramusculair gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Respiratory Syncytial Virus Vaccines",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134994",
  "excipients": [
    "FENOXYETHANOL",
    "MANNITOL (D-) (E 421)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 80 (E 433)",
    "SACCHAROSE",
    "TROMETAMOL",
    "TROMETAMOLHYDROCHLORIDE",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "RECOMBINANT RESPIRATOIR SYNCYTIEEL VIRUS SUBGROEP A PREFUSIE F ANTIGEEN 847A",
    "RECOMBINANT RESPIRATOIR SYNCYTIEEL VIRUS SUBGROEP B PREFUSIE F ANTIGEEN 847B"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/08/23",
  "procedure_number": "EMEA/H/C/006027",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1752",
  "additional_monitoring": "Y"
}

See everything about respiratorisches-synzytial-virus impfstoffe.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.